Dear Colleagues,

Autoimmune and/or inflammatory diseases (AIID) include non-organ-specific systemic autoimmune diseases, including connective tissue disorders (such as rheumatoid arthritis, systemic lupus, Sjögren’s syndrome, systemic sclerosis, and inflammatory myopathies) and vasculitides (such as ANCA-associated vasculitides, cryoglobulinemia, IgA vasculitis, periarteritis nodosa, giant cell arteritis, etc.). Several other diseases are limited to one single organ through autoimmunity (organ-specific autoimmune diseases such as Hashimoto thyroiditis) or inflammation (such as inflammatory bowel diseases). We have to also mention the group of autoinflammatory diseases which have recently been enriched with a new entity called VEXAS.

While the relationships between AIID and cancers (solid and/or hematological) have been studied now for several decades, recent years are marked by an increasing amount of robust scientific data and researches concerning this association. For example, the association between systemic sclerosis and cancer is now well documented, while myelodysplastic syndromes are now considered as conditions favoring inflammatory diseases. Therefore, recent years have been very exciting and promising, reinforced by the emerging interest regarding the role of the immune system against cancer. Furthermore, immune checkpoint inhibitors are powerful therapeutic weapons against cancer, but they may also induce autoimmune adverse events, close to classical AIID. Therefore, the association between AIID and cancer may appear as a double-edged sword, and the concept of autoimmune paraneoplastic syndrome is emerging in several fields (notable, neurological, and systemic diseases).

This topic aims to outline the association between AIID and cancers (epidemiology, clinical characteristics, pathophysiological mechanisms, and therapeutic features).

Welcome to all relevant articles, including research articles, review articles as well as short communications.

Prof. Dr. Philippe Guilpain
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• connective tissue disorders
• lupus
• Sjögren’s syndrome
• inflammatory myopathy
• systemic sclerosis
• vasculitides
•  rheumatoid arthritis
• ANCA-associated vasculitides
• periarteritis nodosa
• IgA vasculitis
• Giant cell arteritis
• VEXAS
• autoinflammatory diseases
• organ specific autoimmune diseases
• thyroiditis
• myasthenia gravis
• inflammatory bowel diseases
• paraneoplastic syndromes
• solid cancers
• hematological cancers
• myelodysplastic syndromes